Results 111 to 120 of about 1,320,527 (284)

Mineralocorticoid Receptor Antagonists in Dialysis

American Journal of Nephrology
Background: Aldosterone regulates genes controlling fluid and electrolyte balance through mineralocorticoid receptor (MR) activation. Sustained MR activation promotes inflammation, fibrosis, sodium retention, and myocardial remodeling. MR antagonists (MRAs) block aldosterone binding in the kidney, heart, and vasculature and are classified as steroidal ...
Elias John Elenjickal, Thomas A. Mavrakanas   +1 more
openaire   +1 more source

eGFR slope as predictor of mortality in heart failure patients

ESC Heart Failure, Volume 12, Issue 2, Page 1217-1226, April 2025.
Abstract Aims Heart failure (HF) leads to an imbalance between heart and kidney function, resulting in poor outcomes. However, the prognostic significance of the estimated glomerular filtration rate (eGFR) trajectory in HF patients remains unclear. We analysed electronic health records (EHRs) of real‐world HF patients, assessing eGFR trajectories and ...
Sofie Verstreken, Monika Beles, Clara L. Oeste, Ana Moya, Imke Masuy, Riet Dierckx, Ward Heggermont, Jeroen Dauw, Dries Hens, Jozef Bartunek, Marc Vanderheyden   +10 more
wiley   +1 more source

Radiolabelled GLP-1 receptor antagonist binds to GLP-1 receptor-expressing human tissues. [PDF]

, 2014
PURPOSE Radiolabelled glucagon-like peptide 1 (GLP-1) receptor agonists have recently been shown to successfully image benign insulinomas in patients.
Waser, Beatrice, Reubi, Jean-Claude
core   +2 more sources

Comparative performance of risk prediction indices for mortality or readmission following heart failure hospitalization

ESC Heart Failure, Volume 12, Issue 2, Page 1227-1236, April 2025.
Comparative performance of 7 risk prediction indices in patients hospitalized for heart failure. In this cohort of 1206 patients, the LENT index offered the greatest discrimination, calibration, and overall accuracy in predicting 30‐day composite all‐cause mortality or readmission following hospitalization for heart failure.
Tauben Averbuch, Ali Zafari, Shofiqul Islam, Shun Fu Lee, Rajiv Sankaranarayanan, Stephen J Greene, Mamas A Mamas, Ambarish Pandey, Harriette GC Van Spall   +8 more
wiley   +1 more source

Effect of Mineralocorticoid receptor antagonism (MRA) on aldosterone-interleukin 6 axis in heart failure; second opinion. A case-control study

The Egyptian Journal of Internal Medicine
Background In cases of heart failure characterized by reduced ejection fraction (HFrEF), heightened levels of aldosterone negatively impact the progression of heart failure.
H. ElSawi, S. Zidan, A. Elborolosy
doaj   +1 more source

Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists

, 2017
Juan Carlos Yugar-Toledo,1 Rodrigo Modolo,2 Ana Paula de Faria,2 Heitor Moreno2 1São José do Rio Preto Medicine School – FAMERP, São José do Rio Preto, 2School of Medical Sciences, University of Campinas (UNICAMP ...
Modolo R, de Faria AP, Moreno H, Yugar-Toledo JC   +3 more
core  

Long‐term cardiovascular outcomes of immune checkpoint inhibitor‐related myocarditis: A large single‐centre analysis

ESC Heart Failure, Volume 12, Issue 2, Page 1237-1245, April 2025.
Abstract Aims Immune checkpoint inhibitors (ICI) are the cornerstone of modern oncology; however, side effects such as ICI‐related myocarditis (irM) can be fatal. Recently, Bonaca proposed criteria for irM; however, it is unknown if they correlate well with cardiovascular (CV) ICI‐related adverse events.
Lorenzo Braghieri, Ahmad Gharaibeh, Lubika Nkashama, Abdelrahman Abushouk, Osama Abushawer, Amir Mehdizadeh‐Shrifi, Bianca Honnekeri, Cassandra Calabrese, Venu Menon, Pauline Funchain, Patrick Collier, Diego Sadler, Rohit Moudgil   +12 more
wiley   +1 more source

Myocardial inflammation is associated with impaired mitochondrial oxidative capacity in ischaemic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1246-1255, April 2025.
Abstract Aims Myocardial inflammation and impaired mitochondrial oxidative capacity are hallmarks of heart failure (HF) pathophysiology. The extent of myocardial inflammation in patients suffering from ischaemic cardiomyopathy (ICM) or dilated cardiomyopathy (DCM) and its association with mitochondrial energy metabolism are unknown.
Julius Borger, Elric Zweck, Constanze Moos, Patrick Horn, Fabian Voß, Heinz‐Peter Schultheiss, Jacob Eifer Møller, Udo Boeken, Hug Aubin, Artur Lichtenberg, Malte Kelm, Michael Roden, Amin Polzin, Ralf Westenfeld, Julia Szendroedi, Daniel Scheiber   +15 more
wiley   +1 more source

Resolution of foveal detachment in dome-shaped macula after treatment by spironolactone: report of two cases and mini-review of the literature

Clinical Ophthalmology, 2014
Ali Dirani,1 Alexandre Matet,1 Talal Beydoun,2 Irmela Mantel,1 Francine Behar-Cohen1–3 1Department of Ophthalmology, University of Lausanne, Jules Gonin Eye Hospital, Lausanne, Switzerland; 2Department of Ophthalmology, Hôtel-Dieu de Paris ...
Dirani A, Matet A, Beydoun T, Mantel I, Behar-Cohen F   +4 more
doaj  

Projecting the benefit of vericiguat in PARADIGM‐HF and DAPA‐HF populations: Insights from the VICTORIA trial

ESC Heart Failure, Volume 12, Issue 2, Page 1479-1484, April 2025.
Abstract Aims The VICTORIA trial demonstrated a significant reduction in the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death with vericiguat relative to placebo in high‐risk HF. This study aimed to contextualize treatment effects of vericiguat in populations with varying risk profiles simulated from the PARADIGM ...
Veraprapas Kittipibul, Robert J. Mentz, Rebecca Young, Javed Butler, Justin A. Ezekowitz, Carolyn S.P. Lam, Piotr Ponikowski, Adriaan Voors, Stefano Corda, Ciaran McMullan, Christopher M. O'Connor, Kevin J. Anstrom, Paul W. Armstrong, for the VICTORIA Study Group   +13 more
wiley   +1 more source